T[o the]{.smallcaps} E[ditor]{.smallcaps}--- We recognize the efforts by Bartsch et al \[[@CIT773C1]\] to evaluate fidaxomicin (DIFICID). The conclusions drawn by the authors, however, warrant reexamination in light of numerous clinical and methodological problems.

Clinically, the "all-or-none" treatment approach used in the decision model does not accurately represent real-world treatment patterns. The model assumes if a treatment fails, a second course will be effective, thus biasing the results toward a relatively ineffective first-line treatment.

The severity classification used by the authors also limits the applicability of this model and does not reflect Society for Healthcare Epidemiology of American/Infectious Diseases Society of America guidelines, nor does it provide a reliable way to classify patients at the onset of treatment \[[@CIT773C2]\].

Given the efficacy data in Table 1 \[[@CIT773C1]\], it should be mathematically impossible to derive the result that fidaxomicin is less effective. It seems likely that there is a typographical error in either the table or model calculations, or both.

The selection of a NAP1/BI/027 frequency of 50% considerably overestimates the burden of this strain of *C. difficile*. Current estimates of 22%--34% suggest that the prevalence of the BI strain is declining, with the United States likely experiencing a period of endemicity rather than epidemicity and outbreaks \[[@CIT773C3]--[@CIT773C5]\].

We also question the use of utility weights for noninfectious diarrhea (range, 0.817--0.92, Table 1 \[[@CIT773C1]\]) as a proxy for *C. difficile*--associated diarrhea (CDAD). The values in Table 1 present a situation where the utility for nonsevere disease (0.88) is higher than the baseline utility for patients aged ≥65 years (0.84). If this were true, a patient aged ≥65 could potentially have improved quality of life when experiencing an episode of nonsevere CDAD. Other potential, more appropriate utility probabilities can be found in the Tufts Cost-Effectiveness Analysis Registry \[[@CIT773C6]\]. Using inaccurate or widely disparate utility values can significantly magnify errors in output \[[@CIT773C7]\].

Finally, we draw attention to the independently conducted economic analysis of fidaxomicin vs vancomycin recently published by Stranges et al in *Value in Health* \[[@CIT773C8]\]. The two models share several efficacy and cost parameters, the inputs for which vary substantially. The significantly different inputs, combined with a more appropriate clinical scenario, produced a very different cost per quality-adjusted life-year of \$67 576, substantially lower than Bartsch et al\'s \$43.7 million \[[@CIT773C1], [@CIT773C8]\].

We recognize the complexity of modeling treatment patterns in *C. difficile* infection; however, several inappropriate clinical and methodological assumptions significantly limit the value of this work.
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